Physician profile
Christopher Enoch
NPI 1912978503
$4,523.97
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $177 · 2021: $411 · 2022: $836 · 2023: $1,173 · 2024: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Education: $12.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.60 |
| Education | $12.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $741.84 | 2022-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $515.11 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $503.92 | 2019-2024 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $454.50 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $299.50 | 2019-2023 | Jynarque |
| Vifor Pharma, INC. | $258.69 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $246.64 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $207.45 | 2021-2023 | Acthar |
| Glaxosmithkline, LLC. | $179.73 | 2021-2023 | Benlysta, Jesduvroq |
| Mallinckrodt Enterprises LLC | $178.42 | 2019 | |
| Amgen INC. | $165.25 | 2022-2024 | Tavneos, Krystexxa |
| Akebia Therapeutics INC | $130.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $105.83 | 2020-2024 | |
| Fresenius USA Marketing, INC. | $104.59 | 2019-2023 | Korsuva, Velphoro |
| Bard Peripheral Vascular, INC. | $101.23 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.57 | 2023-2024 | Jardiance |
| Daiichi Sankyo INC. | $51.82 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $38.80 | 2021-2023 | |
| Genzyme Corporation | $37.82 | 2022-2023 | |
| Lilly USA, LLC | $29.30 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $24.68 | 2021 | |
| Ani Pharmaceuticals, INC. | $20.02 | 2024 | Purified Cortrophin Gel |
| Ardelyx, INC. | $18.16 | 2024 | Ibsrela |
| Opko Pharmaceuticals, LLC | $16.09 | 2022 | |
| Horizon Therapeutics Plc | $14.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Enoch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.